[HTML][HTML] Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics
JI Lai, YJ Tseng, MH Chen, CYF Huang… - Frontiers in …, 2020 - frontiersin.org
P-glycoprotein (also known as multidrug resistance protein 1 (MDR1) or ATP-binding
cassette sub-family B member 1 (ABCB1) plays a crucial role in determining response …
cassette sub-family B member 1 (ABCB1) plays a crucial role in determining response …
Current advances of nitric oxide in cancer and anticancer therapeutics
J Mintz, A Vedenko, O Rosete, K Shah, G Goldstein… - Vaccines, 2021 - mdpi.com
Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical
functions in the body. There are markedly conflicting findings in the literature regarding the …
functions in the body. There are markedly conflicting findings in the literature regarding the …
Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
[HTML][HTML] The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: Future …
J Goebel, J Chmielewski, CA Hrycyna - Cancer Drug Resistance, 2021 - ncbi.nlm.nih.gov
The ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp) and ABCG2 are
multidrug transporters that confer drug resistance to numerous anti-cancer therapeutics in …
multidrug transporters that confer drug resistance to numerous anti-cancer therapeutics in …
Understanding breast cancer: From conventional therapies to repurposed drugs
B Costa, I Amorim, F Gärtner, N Vale - European Journal of Pharmaceutical …, 2020 - Elsevier
Breast cancer is the most common cancer among women and is considered a developed
country disease. Moreover, is a heterogenous disease, existing different types and stages of …
country disease. Moreover, is a heterogenous disease, existing different types and stages of …
[HTML][HTML] Nitric oxide system and bronchial epithelium: more than a barrier
MA Bayarri, J Milara, C Estornut, J Cortijo - Frontiers in physiology, 2021 - frontiersin.org
Airway epithelium forms a physical barrier that protects the lung from the entrance of inhaled
allergens, irritants, or microorganisms. This epithelial structure is maintained by tight …
allergens, irritants, or microorganisms. This epithelial structure is maintained by tight …
Inhibitors of phosphodiesterase as cancer therapeutics
T Peng, J Gong, Y Jin, Y Zhou, R Tong, X Wei… - European journal of …, 2018 - Elsevier
Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in …
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in …
[HTML][HTML] New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil
M Cruz-Burgos, A Losada-Garcia… - Frontiers in …, 2021 - frontiersin.org
The use of already-approved drugs to treat new or alternative diseases has proved to be
beneficial in medicine, because it reduces both drug development costs and timelines. Most …
beneficial in medicine, because it reduces both drug development costs and timelines. Most …
RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse
J Cho, HY Min, HJ Lee, SY Hyun… - The Journal of …, 2021 - Am Soc Clin Investig
Slow-cycling/dormant cancer cells (SCCs) have pivotal roles in driving cancer relapse and
drug resistance. A mechanistic explanation for cancer cell dormancy and therapeutic …
drug resistance. A mechanistic explanation for cancer cell dormancy and therapeutic …
Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling
Purpose: Docetaxel plays an indispensable role in the management of advanced prostate
cancer. However, more than half of patients do not respond to docetaxel, and those good …
cancer. However, more than half of patients do not respond to docetaxel, and those good …